Johnson & Johnson (JNJ) Earnings Dates, Call Summary & Reports

Compare

27,696 Followers

Earnings Data

Report Date

Apr 14, 2026

Before Open (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

2.69

Last Year’s EPS

2.77

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 13 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Jan 21, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call highlights a dominant message of accelerating, portfolio-driven growth: robust revenue and adjusted EPS growth, strong free cash flow, numerous approvals and late-stage programs, and notable commercial momentum across oncology, immunology, neuroscience, and MedTech. Management provided constructive 2026 guidance, reiterated long-term ambition (double-digit growth by the end of the decade), and outlined capital deployment and the orthopedics separation. Offsetting risks include material STELARA biosimilar erosion (a substantial multi-hundred-basis-point headwind), elevated litigation and one-time charges, tariff pressures, competitive dynamics in select MedTech areas, and modest share-count dilution. On balance, the positives — broad-based commercial strength, pipeline and approval milestones, robust cash generation, and clear guidance — materially outweigh the near-term headwinds.

Company Guidance

Management guided 2026 operational sales growth of 5.7%–6.7% (midpoint 6.2%, ~$100.0B) with acquisitions/divestitures adding ~30 bps (adjusted operational midpoint 5.9%) and a fifty‑third week worth ~100 bps; reported sales growth is expected 6.2%–7.2% (midpoint $100.5B, 6.7%). They forecast free cash flow of ≈$21B, an adjusted pretax operating margin improvement of at least 50 bps, net interest expense of $300M–$400M, net other income of $1.0–$1.2B, and an effective tax rate of 17.5%–18.5%. Adjusted operational EPS guidance is $11.28–$11.48 (≈5.5% growth at the midpoint) and reported adjusted EPS midpoint is $11.53 after a $0.15 FX benefit; diluted share count is expected to be ~2.44B (incremental dilution a little over $0.05 headwind). Management also called out ~$500M of full‑year medtech tariffs, plans to invest operating efficiencies into the business, and said sales growth should be fairly consistent through the year with a stronger Q4 and higher EPS growth in H2 versus H1.

Strong Full-Year and Q4 Revenue

Full-year 2025 worldwide sales of $94.2 billion, up 5.3% operationally; Q4 2025 sales of $24.6 billion, up 7.1% operationally despite a ~650 basis point headwind from STELARA.

Adjusted Earnings and EPS Growth

Full-year adjusted net earnings of $26.2 billion and adjusted diluted EPS of $10.79, up 8.1% year-over-year; Q4 adjusted diluted EPS of $2.46, up 21.5% versus prior year.

Robust Free Cash Flow and Balance Sheet Strength

Generated $19.7 billion of free cash flow in 2025; ended the year with ~$20 billion in cash and marketable securities and net debt of ~$28 billion; company expects free cash flow of ~ $21 billion in 2026.

Innovation and Pipeline Momentum

In 2025 J&J secured 51 approvals, filed 32 submissions across major markets, delivered positive readouts from 17 key studies, and initiated 11 new Phase III programs — signaling substantial R&D productivity.

Oncology Outperformance

Oncology delivered ~21% operational sales growth in 2025; DARZALEX is the largest pharma product with annual sales > $14 billion (full-year growth ~22–24%); CARVICTI treated >10,000 patients and Carvictee sales reached $555 million, up 63.2% in the quarter.

Immunology Momentum (Tremfya and Pipeline)

Tremfya full-year sales accelerated to > $5 billion and Q4 growth of ~65.4% (quarter), becoming the fastest-growing IL-23 therapy; company projects Tremfya could exceed $10 billion in peak sales and expects approval/launch of oral icotide in 2026.

Neuroscience and New Launches

Spravato continued strong growth (year-over-year growth cited at 57%–67.8% depending on period) with >200,000 patients treated worldwide; CAPLYTA launched in the US for adjunctive major depressive disorder and is viewed as a ~$5 billion peak year opportunity.

MedTech Growth and Product Momentum

MedTech sales of $8.8 billion in the quarter increased 5.8% operationally; cardiovascular grew ~15% for the year with Abiomed (18.3% growth) and Shockwave (22.9%); Surgery and Vision showed accelerating momentum with 15 major launches and >40 regulatory approvals in 2025.

2026 Guidance and Long-Term Outlook

Guidance for 2026 operational sales growth of 5.7%–6.7% (midpoint ~$100 billion / 6.2% operational), adjusted EPS growth of ~5.5% at midpoint, and management reiterates line of sight to double-digit revenue growth by the end of the decade.

Capital Allocation and Strategic Actions

Invested > $32 billion in R&D and M&A in 2025 (including Intracellular and Halda), started new manufacturing facilities in the U.S., and progressed a planned orthopedics separation targeted for mid-2027 to sharpen portfolio focus.

Johnson & Johnson (JNJ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JNJ Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Apr 14, 2026	2026 (Q1)	2.69 / -	2.77	―	―	―
Jan 21, 2026	2025 (Q4)	2.46 / 2.46	2.04	20.59% (+0.42)
Oct 14, 2025	2025 (Q3)	2.76 / 2.80	2.42	15.70% (+0.38)
Jul 16, 2025	2025 (Q2)	2.68 / 2.77	2.82	-1.77% (-0.05)
Apr 15, 2025	2025 (Q1)	2.58 / 2.77	2.71	2.21% (+0.06)
Jan 22, 2025	2024 (Q4)	1.99 / 2.04	2.29	-10.92% (-0.25)
Oct 15, 2024	2024 (Q3)	2.21 / 2.42	2.66	-9.02% (-0.24)
Jul 17, 2024	2024 (Q2)	2.71 / 2.82	2.8	0.71% (+0.02)	―	―
Apr 16, 2024	2024 (Q1)	2.66 / 2.71	2.68	1.12% (+0.03)	―	―
Jan 23, 2024	2023 (Q4)	2.28 / 2.29	2.35	-2.55% (-0.06)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JNJ Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jan 21, 2026	$218.21	$218.01	-0.09%
Oct 14, 2025	$189.70	$189.64	-0.03%
Jul 16, 2025	$153.07	$162.55	+6.19%
Apr 15, 2025	$150.97	$150.25	-0.48%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.